Foundation Medicine Inc (NASDAQ:FMI) COO Steven J. Kafka sold 29,791 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $61.55, for a total value of $1,833,636.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Steven J. Kafka also recently made the following trade(s):
- On Tuesday, January 2nd, Steven J. Kafka sold 157 shares of Foundation Medicine stock. The shares were sold at an average price of $64.00, for a total value of $10,048.00.
Shares of Foundation Medicine Inc (FMI) opened at $74.90 on Friday. The firm has a market capitalization of $2,720.00, a PE ratio of -16.76 and a beta of -0.03. The company has a quick ratio of 2.03, a current ratio of 2.24 and a debt-to-equity ratio of 0.47. Foundation Medicine Inc has a 1-year low of $22.40 and a 1-year high of $75.20.
Several analysts have weighed in on FMI shares. Zacks Investment Research raised Foundation Medicine from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a report on Monday, November 6th. BidaskClub raised Foundation Medicine from a “hold” rating to a “buy” rating in a report on Tuesday, December 12th. Finally, Goldman Sachs Group started coverage on Foundation Medicine in a report on Monday, January 29th. They issued a “neutral” rating and a $73.00 price target on the stock. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Foundation Medicine presently has an average rating of “Hold” and a consensus target price of $59.80.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fiduciary Trust Co. purchased a new position in shares of Foundation Medicine during the 4th quarter valued at about $205,000. BlueCrest Capital Management Ltd purchased a new position in shares of Foundation Medicine during the 4th quarter valued at about $239,000. Financial Advocates Investment Management purchased a new position in shares of Foundation Medicine during the 4th quarter valued at about $239,000. UBS Asset Management Americas Inc. purchased a new position in shares of Foundation Medicine during the 4th quarter valued at about $241,000. Finally, Raymond James & Associates purchased a new position in shares of Foundation Medicine during the 4th quarter valued at about $244,000. 33.12% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Foundation Medicine Inc (FMI) COO Sells $1,833,636.05 in Stock” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://ledgergazette.com/2018/02/18/foundation-medicine-inc-fmi-coo-sells-1833636-05-in-stock.html.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.